Gilead Sciences, Inc. (GILD) Shares Sold by Stevens First Principles Investment Advisors

Stevens First Principles Investment Advisors decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 48,051 shares of the biopharmaceutical company’s stock after selling 1,585 shares during the quarter. Gilead Sciences accounts for about 2.1% of Stevens First Principles Investment Advisors’ holdings, making the stock its 17th biggest position. Stevens First Principles Investment Advisors’ holdings in Gilead Sciences were worth $3,893,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Sanders Capital LLC acquired a new position in shares of Gilead Sciences in the third quarter valued at approximately $427,585,000. Renaissance Technologies LLC grew its position in shares of Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after purchasing an additional 2,700,600 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Gilead Sciences by 50.0% in the second quarter. The Manufacturers Life Insurance Company now owns 6,191,622 shares of the biopharmaceutical company’s stock valued at $438,244,000 after purchasing an additional 2,062,886 shares during the last quarter. Finally, BlackRock Inc. grew its position in shares of Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after purchasing an additional 1,937,031 shares during the last quarter. Hedge funds and other institutional investors own 75.94% of the company’s stock.

In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total value of $5,509,508.29. Following the completion of the transaction, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 461,666 shares of company stock worth $34,072,567. Company insiders own 1.30% of the company’s stock.

GILD has been the topic of several research reports. ValuEngine downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 13th. Royal Bank of Canada assumed coverage on Gilead Sciences in a research report on Thursday, September 14th. They set an “outperform” rating and a $94.00 price target on the stock. Leerink Swann reissued a “market perform” rating and set a $87.00 price target (up previously from $82.00) on shares of Gilead Sciences in a research report on Wednesday, September 20th. Mizuho reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, September 29th. Finally, Jefferies Group reissued a “hold” rating and set a $93.00 price target on shares of Gilead Sciences in a research report on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $85.03.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $78.71 on Thursday. The firm has a market capitalization of $102,790.00, a price-to-earnings ratio of 8.95, a price-to-earnings-growth ratio of -1.58 and a beta of 1.13. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s revenue was down 13.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.75 EPS. equities research analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.64%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.66%.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.com-unik.info/2018/01/11/gilead-sciences-inc-gild-shares-sold-by-stevens-first-principles-investment-advisors.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit